Open access
Open access
Powered by Google Translator Translator

Chest Medicine

Comprehensive Review | Pneumonia

9 Apr, 2021 | 03:14h | UTC

Pneumonia – Nature Reviews Disease Primers (free for a limited period)

Try this link if the above is paywalled.

 

Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19

12 Apr, 2021 | 01:24h | UTC

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial – The Lancet Respiratory Medicine

Commentary: Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19 – The Lancet Respiratory Medicine

 

Commentary on Twitter

 

[Preprint] CoronaVac is 50% effective for reducing symptomatic SARS-CoV-2 infection after the first dose in the setting of high P.1 variant transmission in Brazil

9 Apr, 2021 | 03:36h | UTC

Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study – medRxiv

 

Commentary on Twitter (thread – click for more)

 

Commentary | Distinguishing the real from the hyperglycemia: does COVID-19 induce diabetes?

9 Apr, 2021 | 03:28h | UTC

Distinguishing the real from the hyperglycaemia: does COVID-19 induce diabetes? – The Lancet Diabetes & Endocrinology

 

The NIH COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19

9 Apr, 2021 | 03:35h | UTC

The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19 – NIH COVID-19 Treatment Guidelines

 

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions

8 Apr, 2021 | 09:14h | UTC

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records – The Lancet Psychiatry

Commentaries: 1 in 3 Covid-19 patients are diagnosed with a neuropsychiatric condition in the next six months, large study finds – STAT AND A longer look at COVID-19 and neuropsychiatric outcomes – The Lancet Psychiatry AND Largest study to date suggests link between COVID-19 infection and subsequent mental health and neurological conditions – The Lancet AND Covid-19: One in three has neurological or psychiatric condition diagnosed after covid infection, study finds – The BMJ AND One in three survivors of severe Covid diagnosed with mental health condition – The Guardian AND Covid-19 linked to depression and dementia, study suggests – BBC AND Expert reaction to observational study looking at neurological and psychiatric outcomes 6 months after COVID-19 – Science Media Centre AND 1 in 3 COVID Survivors Struggle With Mental Health Issues Months Later – HealthDay

 

Commentary on Twitter (thread – click for more)

 

Cohort study: One in ten have long-term effects 8 months following mild COVID-19

8 Apr, 2021 | 09:12h | UTC

One in ten have long-term effects 8 months following mild COVID-19 – Karolinska Institutet

Original study: Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers – JAMA

 

Commentary on Twitter

 

Study: Outdoor transmission accounts for 0.1% of Covid-19 cases

8 Apr, 2021 | 09:11h | UTC

Outdoor transmission accounts for 0.1% of State’s Covid-19 cases – The Irish Times

Related: Systematic review: Outdoor transmission of SARS-CoV-2 and other respiratory viruses. “The odds of indoor transmission was very high compared to outdoors (18.7 times)”

 

UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca

8 Apr, 2021 | 09:05h | UTC

UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca – GOV.UK

Original report: MHRA issues new advice, concluding a possible link between COVID-19 Vaccine AstraZeneca and extremely rare, unlikely to occur blood clots – Medicines and Healthcare products Regulatory Agency

Commentary: Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre

 

Commentary on Twitter

 

WHO Interim statement: A causal relationship between the AstraZeneca COVID-19 vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed

8 Apr, 2021 | 09:09h | UTC

Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. The benefits of the vaccine continue to outweigh the risks for people who receive it.

8 Apr, 2021 | 09:07h | UTC

AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets – European Medicines Agency

Commentaries: In rare instances, AstraZeneca’s Covid-19 vaccine linked to blood clots, regulators say – STAT AND Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre

 

JCVI statement on use of the AstraZeneca COVID-19 vaccine: “JCVI currently advises that it is preferable for adults aged <30 years to be offered an alternative COVID-19 vaccine, if available.”

8 Apr, 2021 | 09:02h | UTC

JCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021 – GOV.UK

Commentaries: Covid: Under-30s offered alternative to Oxford-AstraZeneca jab – BBC AND Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre

 

Video: Coronavirus Variants and Vaccines

8 Apr, 2021 | 09:00h | UTC

Coronavirus Variants and Vaccines – JAMA

 

Study finds low risk of venous thromboembolism in outpatients with Covid-19 – researchers advise against the use of anticoagulants outside clinical trials

8 Apr, 2021 | 08:59h | UTC

Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California – JAMA Internal Medicine

Commentaries: VTE Related to SARS-CoV-2 Infection Less Of a Problem in Outpatients – TCTMD AND No Increase Seen in Outpatient VTE for SARS-CoV-2-Positive Patients – Physician’s Weekly

 

Commentary on Twitter (thread – Click for more)

https://twitter.com/gjgeersing/status/1379740743951134721

 

CDC Updated Guidance: “It is possible for people to be infected through contact with contaminated surfaces or objects, but the risk is generally considered to be low”

7 Apr, 2021 | 02:00h | UTC

Science Brief: SARS-CoV-2 and Surface (Fomite) Transmission for Indoor Community Environments – Centers for Disease Control and Prevention

Related: Catching COVID from surfaces is very unlikely. So perhaps we can ease up on the disinfecting – The Conversation AND Coronavirus is in the air — there’s too much focus on surfaces – Nature AND COVID-19 rarely spreads through surfaces. So why are we still deep cleaning? – Nature

 

ACP Guidance: Appropriate Use of Short-Course Antibiotics in Common Infections

6 Apr, 2021 | 01:12h | UTC

Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians – Annals of Internal Medicine

Summary for Patients: Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians

News release: ACP best practice advice: Shorter course of antibiotics may be appropriate for some common infection – American College of Physicians

 

Differences in susceptibility of circulating SARS-CoV-2 variants B.1.1.7 and B.1.351 to neutralization by convalescent plasma or vaccinee (Sinopharm or Sinovac) serum

7 Apr, 2021 | 01:57h | UTC

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization – New England Journal of Medicine

Related studies: Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination – Nature Medicine AND Pfizer coronavirus vaccine found to be moderately less effective against B.1.351 variant AND SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination AND B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well. AND RCT: Oxford/AstraZeneca vaccine does not protect against mild-to-moderate Covid-19 due to the B.1.351 variant AND New study of Coronavirus variants predicts virus evolving to escape current vaccines, treatments AND Moderna COVID-19 vaccine may be less effective against variant found in South Africa

 

Commentary on Twitter

https://twitter.com/hildabast/status/1379597338956603400

 

Guidance on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination

7 Apr, 2021 | 01:48h | UTC

Guidance produced from the Expert Haematology Panel (EHP) focussed on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination – British Society of Haematology

Related: Exceedingly rare side effects reported with AstraZeneca vaccine in the UK – 22 cases of cerebral venous sinus thrombosis with low levels of platelets out of 18 million vaccinated individuals

 

Commentary on Twitter

https://twitter.com/trishgreenhalgh/status/1379414362700517385

 

Opinion | New COVID variants have changed the game, and vaccines will not be enough. We need global ‘maximum suppression’

7 Apr, 2021 | 01:44h | UTC

New COVID variants have changed the game, and vaccines will not be enough. We need global ‘maximum suppression’ – The Conversation

 

Commentary on Twitter

 

Antibody persistence for at least 6 months after the second dose of mRNA vaccine (Moderna) for Covid-19

7 Apr, 2021 | 01:54h | UTC

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 – New England Journal of Medicine

Commentary: Moderna COVID Vaccine Offers Protection for at Least 6 Months: Study – HealthDay

Related: [Press release – not published yet] Pfizer/BioNTech vaccine is 91% effective for at least 6 months

 

Commentary on Twitter

 

What’s the new coronavirus variant in India and how should it change their COVID response?

7 Apr, 2021 | 01:42h | UTC

What’s the new coronavirus variant in India and how should it change their COVID response? – The Conversation

 

Large study showed no association between blood group types and increased risk of Covid-19

7 Apr, 2021 | 01:41h | UTC

Association of Sociodemographic Factors and Blood Group Type With Risk of COVID-19 in a US Population – JAMA Network Open

 

Commentary on Twitter

 

Leadership Essentials for CHEST Medicine Professionals: Models, Attributes, and Styles

6 Apr, 2021 | 01:10h | UTC

Leadership Essentials for CHEST Medicine Professionals: Models, Attributes, and Styles – CHEST

Commentary and Summary: Leadership 101 – Commitments, Character, Competencies – Journal Feed

 

CDC Report: Community Transmission of SARS-CoV-2 Associated with a Local Bar Opening Event

6 Apr, 2021 | 01:29h | UTC

Community Transmission of SARS-CoV-2 Associated with a Local Bar Opening Event — Illinois, February 2021 – CDC Morbidity and Mortality Weekly Report

Commentaries: Illinois bar opening event linked to 46 Covid-19 cases, a school closure and hospitalization, CDC report says – CNN AND Bar opening linked to 29 COVID-19 diagnoses among staff and patrons, 17 more across the community affecting school, nursing home – Science Speaks: Global ID News AND 46 COVID-19 cases linked to one indoor bar event in rural Illinois: CDC – The Hill

Related: Why indoor spaces are still prime COVID hotspots – Nature

 

Consensus Statement: Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery

6 Apr, 2021 | 00:54h | UTC

Perioperative management of patients with pulmonary hypertension undergoing non-cardiothoracic, non-obstetric surgery: a systematic review and expert consensus statement – British Journal of Anaesthesia

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.